Sphingomab Mitigates the Multiple Pathologies of Age-Related Macular Degeneration
LPATH THERAPEUTICS, INC. · Department of Health and Human Services
Phase I2007$125,844
DESCRIPTION (provided by applicant): Therapies that target Vascular Endothelial Growth Factor (VEGF) represent a recent, significant advance in the treatment of exudative age-related macular degeneration (AMD). However,…